Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 85 entries
Sorted by: Best Match Show Resources per page
Salutary cardiovascular effects of antidiabetic drugs: myth or fact?.

Journal of hypertension

Ruiz-Hurtado G, Ruilope LM.
PMID: 26425833
J Hypertens. 2015 Nov;33(11):2198-9. doi: 10.1097/HJH.0000000000000741.

No abstract available.

Cite
Ruiz-Hurtado G, Ruilope LM. Salutary cardiovascular effects of antidiabetic drugs: myth or fact?. J Hypertens. 2015;33(11):2198-9doi: 10.1097/HJH.0000000000000741.
Ruiz-Hurtado, G., & Ruilope, L. M. (2015). Salutary cardiovascular effects of antidiabetic drugs: myth or fact?. Journal of hypertension, 33(11), 2198-9. https://doi.org/10.1097/HJH.0000000000000741
Ruiz-Hurtado, Gema, and Ruilope, Luis M. "Salutary cardiovascular effects of antidiabetic drugs: myth or fact?." Journal of hypertension vol. 33,11 (2015): 2198-9. doi: https://doi.org/10.1097/HJH.0000000000000741
Ruiz-Hurtado G, Ruilope LM. Salutary cardiovascular effects of antidiabetic drugs: myth or fact?. J Hypertens. 2015 Nov;33(11):2198-9. doi: 10.1097/HJH.0000000000000741. PMID: 26425833.
Copy Download .nbib Format: NLM
Expertise: No Longer a Sine Qua Non for Guideline Authors?.

Hypertension (Dallas, Tex. : 1979)

Messerli FH, Hofstetter L, Agabiti-Rosei E, Burnier M, Elliott WJ, Franklin SS, Grodzicki T, Kario K, Kjeldsen SE, Kostis JB, Laurent S, Leenen FH, Lund-Johansen P, Mancia G, Narkiewicz K, Papademetriou V, Parati G, Poulter N, Redon J, Rimoldi SF, Ruilope LM, Schiffrin EL, Schmieder RE, Schwartz AB, Sever P, Sowers JR, Staessen JA, Wang J, Weber M, Williams B.
PMID: 28652465
Hypertension. 2017 Aug;70(2):235-237. doi: 10.1161/HYPERTENSIONAHA.117.09470. Epub 2017 Jun 26.

No abstract available.

Cite
Messerli FH, Hofstetter L, Agabiti-Rosei E, et al. Expertise: No Longer a Sine Qua Non for Guideline Authors?. Hypertension. 2017;70(2):235-237doi: 10.1161/HYPERTENSIONAHA.117.09470.
Messerli, F. H., Hofstetter, L., Agabiti-Rosei, E., Burnier, M., Elliott, W. J., Franklin, S. S., Grodzicki, T., Kario, K., Kjeldsen, S. E., Kostis, J. B., Laurent, S., Leenen, F. H., Lund-Johansen, P., Mancia, G., Narkiewicz, K., Papademetriou, V., Parati, G., Poulter, N., Redon, J., Rimoldi, S. F., Ruilope, L. M., Schiffrin, E. L., Schmieder, R. E., Schwartz, A. B., Sever, P., Sowers, J. R., Staessen, J. A., Wang, J., Weber, M., & Williams, B. (2017). Expertise: No Longer a Sine Qua Non for Guideline Authors?. Hypertension (Dallas, Tex. : 1979), 70(2), 235-237. https://doi.org/10.1161/HYPERTENSIONAHA.117.09470
Messerli, Franz H, et al. "Expertise: No Longer a Sine Qua Non for Guideline Authors?." Hypertension (Dallas, Tex. : 1979) vol. 70,2 (2017): 235-237. doi: https://doi.org/10.1161/HYPERTENSIONAHA.117.09470
Messerli FH, Hofstetter L, Agabiti-Rosei E, Burnier M, Elliott WJ, Franklin SS, Grodzicki T, Kario K, Kjeldsen SE, Kostis JB, Laurent S, Leenen FH, Lund-Johansen P, Mancia G, Narkiewicz K, Papademetriou V, Parati G, Poulter N, Redon J, Rimoldi SF, Ruilope LM, Schiffrin EL, Schmieder RE, Schwartz AB, Sever P, Sowers JR, Staessen JA, Wang J, Weber M, Williams B. Expertise: No Longer a Sine Qua Non for Guideline Authors?. Hypertension. 2017 Aug;70(2):235-237. doi: 10.1161/HYPERTENSIONAHA.117.09470. Epub 2017 Jun 26. PMID: 28652465.
Copy Download .nbib Format: NLM
Clinical nephrology.

Current opinion in nephrology and hypertension

Ruilope LM.
PMID: 9159091
Curr Opin Nephrol Hypertens. 1997 Mar 01;6(2):119. doi: 10.1097/00041552-199703000-00002.

No abstract available.

Cite
Ruilope LM. Clinical nephrology. Curr Opin Nephrol Hypertens. 1997;6(2):119doi: 10.1097/00041552-199703000-00002.
Ruilope, L. M. (1997). Clinical nephrology. Current opinion in nephrology and hypertension, 6(2), 119. https://doi.org/10.1097/00041552-199703000-00002
Ruilope. "Clinical nephrology." Current opinion in nephrology and hypertension vol. 6,2 (1997): 119. doi: https://doi.org/10.1097/00041552-199703000-00002
Ruilope LM. Clinical nephrology. Curr Opin Nephrol Hypertens. 1997 Mar 01;6(2):119. doi: 10.1097/00041552-199703000-00002. PMID: 9159091.
Copy Download .nbib Format: NLM
Cardiovascular and Renal Links along the Cardiorenal Continuum.

International journal of nephrology

García-Donaire JA, Ruilope LM.
PMID: 21603119
Int J Nephrol. 2011;2011:975782. doi: 10.4061/2011/975782. Epub 2011 Mar 31.

The cardiorenal syndrome includes the widely known relationship between kidney function and cardiovascular disease. A large number of patients have various degrees of heart and kidney dysfunction worldwide, both in developed and developing countries. Disorders affecting one of them...

Cite
García-Donaire JA, Ruilope LM. Cardiovascular and Renal Links along the Cardiorenal Continuum. Int J Nephrol. 2011;2011:975782doi: 10.4061/2011/975782.
García-Donaire, J. A., & Ruilope, L. M. (2011). Cardiovascular and Renal Links along the Cardiorenal Continuum. International journal of nephrology, 2011975782. https://doi.org/10.4061/2011/975782
García-Donaire, José A, and Ruilope, Luis M. "Cardiovascular and Renal Links along the Cardiorenal Continuum." International journal of nephrology vol. 2011 (2011): 975782. doi: https://doi.org/10.4061/2011/975782
García-Donaire JA, Ruilope LM. Cardiovascular and Renal Links along the Cardiorenal Continuum. Int J Nephrol. 2011;2011:975782. doi: 10.4061/2011/975782. Epub 2011 Mar 31. PMID: 21603119; PMCID: PMC3097083.
Copy Download .nbib Format: NLM
Efficacy of Single-Pill Combination of Telmisartan 80 mg and Hydrochlorothiazide 25 mg in Patients with Cardiovascular Disease Risk Factors: A Prospective Subgroup Analysis of a Randomized, Double-Blind, and Controlled Trial.

International journal of hypertension

Bays H, Gao P, Völker B, Mattheus M, Ruilope LM, Zhu D.
PMID: 23653855
Int J Hypertens. 2013;2013:749830. doi: 10.1155/2013/749830. Epub 2013 Apr 04.

Objective. Report of prespecified and post hoc subgroup analyses of a randomized, controlled trial comparing telmisartan 80 mg/hydrochlorothiazide 25 mg (T80/H25) combination therapy with T80 monotherapy, according to the presence of cardiovascular disease (CVD) risk factors. Methods. Hypertensive patients...

Cite
Bays H, Gao P, Völker B, et al. Efficacy of Single-Pill Combination of Telmisartan 80 mg and Hydrochlorothiazide 25 mg in Patients with Cardiovascular Disease Risk Factors: A Prospective Subgroup Analysis of a Randomized, Double-Blind, and Controlled Trial. Int J Hypertens. 2013;2013:749830doi: 10.1155/2013/749830.
Bays, H., Gao, P., Völker, B., Mattheus, M., Ruilope, L. M., & Zhu, D. (2013). Efficacy of Single-Pill Combination of Telmisartan 80 mg and Hydrochlorothiazide 25 mg in Patients with Cardiovascular Disease Risk Factors: A Prospective Subgroup Analysis of a Randomized, Double-Blind, and Controlled Trial. International journal of hypertension, 2013749830. https://doi.org/10.1155/2013/749830
Bays, Harold, et al. "Efficacy of Single-Pill Combination of Telmisartan 80 mg and Hydrochlorothiazide 25 mg in Patients with Cardiovascular Disease Risk Factors: A Prospective Subgroup Analysis of a Randomized, Double-Blind, and Controlled Trial." International journal of hypertension vol. 2013 (2013): 749830. doi: https://doi.org/10.1155/2013/749830
Bays H, Gao P, Völker B, Mattheus M, Ruilope LM, Zhu D. Efficacy of Single-Pill Combination of Telmisartan 80 mg and Hydrochlorothiazide 25 mg in Patients with Cardiovascular Disease Risk Factors: A Prospective Subgroup Analysis of a Randomized, Double-Blind, and Controlled Trial. Int J Hypertens. 2013;2013:749830. doi: 10.1155/2013/749830. Epub 2013 Apr 04. PMID: 23653855; PMCID: PMC3638649.
Copy Download .nbib Format: NLM
Recent advances in the management of hypertension.

F1000 medicine reports

García-Donaire JA, Ruilope LM.
PMID: 20948867
F1000 Med Rep. 2010 Mar 15;2. doi: 10.3410/M2-19.

Recently, there have been several reports related to the adequacy of blood pressure (BP) control in high-risk hypertensive patients. These aspects have been reviewed in the recently published reappraisal of the European Society of Hypertension guidelines, and this short...

Cite
García-Donaire JA, Ruilope LM. Recent advances in the management of hypertension. F1000 Med Rep. 2010;2doi: 10.3410/M2-19.
García-Donaire, J. A., & Ruilope, L. M. (2010). Recent advances in the management of hypertension. F1000 medicine reports, 2. https://doi.org/10.3410/M2-19
García-Donaire, José Antonio, and Ruilope, Luis M. "Recent advances in the management of hypertension." F1000 medicine reports vol. 2 (2010). doi: https://doi.org/10.3410/M2-19
García-Donaire JA, Ruilope LM. Recent advances in the management of hypertension. F1000 Med Rep. 2010 Mar 15;2. doi: 10.3410/M2-19. PMID: 20948867; PMCID: PMC2948385.
Copy Download .nbib Format: NLM
Blood pressure targets in patients with chronic kidney disease: MDRD and AASK now confirming SPRINT.

Clinical kidney journal

Sarafidis P, Loutradis C, Ortiz A, Ruilope LM.
PMID: 32699614
Clin Kidney J. 2020 Feb 25;13(3):287-290. doi: 10.1093/ckj/sfaa015. eCollection 2020 Jun.

Recent American and European hypertension guidelines are not in agreement regarding blood pressure (BP) targets for persons with chronic kidney disease (CKD). Previous analyses from the African American Study on Kidney Disease (AASK) and Modification of Diet in Renal...

Cite
Sarafidis P, Loutradis C, Ortiz A, et al. Blood pressure targets in patients with chronic kidney disease: MDRD and AASK now confirming SPRINT. Clin Kidney J. 2020;13(3):287-290doi: 10.1093/ckj/sfaa015.
Sarafidis, P., Loutradis, C., Ortiz, A., & Ruilope, L. M. (2020). Blood pressure targets in patients with chronic kidney disease: MDRD and AASK now confirming SPRINT. Clinical kidney journal, 13(3), 287-290. https://doi.org/10.1093/ckj/sfaa015
Sarafidis, Pantelis, et al. "Blood pressure targets in patients with chronic kidney disease: MDRD and AASK now confirming SPRINT." Clinical kidney journal vol. 13,3 (2020): 287-290. doi: https://doi.org/10.1093/ckj/sfaa015
Sarafidis P, Loutradis C, Ortiz A, Ruilope LM. Blood pressure targets in patients with chronic kidney disease: MDRD and AASK now confirming SPRINT. Clin Kidney J. 2020 Feb 25;13(3):287-290. doi: 10.1093/ckj/sfaa015. eCollection 2020 Jun. PMID: 32699614; PMCID: PMC7367111.
Copy Download .nbib Format: NLM
Prognostic Relevance of Short-Term Blood Pressure Variability: The Spanish ABPM Registry.

Hypertension (Dallas, Tex. : 1979)

de la Sierra A, Banegas JR, Bursztyn M, Parati G, Stergiou G, Mateu A, Vinyoles E, Segura J, Gorostidi M, Ruilope LM.
PMID: 31983311
Hypertension. 2020 Jan 27;HYPERTENSIONAHA11914508. doi: 10.1161/HYPERTENSIONAHA.119.14508. Epub 2020 Jan 27.

The prognostic relevance of short-term blood pressure (BP) variability in hypertension is not clearly established. We aimed to evaluate the association of short-term BP variability, assessed through ambulatory BP monitoring, with total and cardiovascular mortality in a large cohort...

Cite
de la Sierra A, Banegas JR, Bursztyn M, et al. Prognostic Relevance of Short-Term Blood Pressure Variability: The Spanish ABPM Registry. Hypertension. 2020;HYPERTENSIONAHA11914508doi: 10.1161/HYPERTENSIONAHA.119.14508.
de la Sierra, A., Banegas, J. R., Bursztyn, M., Parati, G., Stergiou, G., Mateu, A., Vinyoles, E., Segura, J., Gorostidi, M., & Ruilope, L. M. (2020). Prognostic Relevance of Short-Term Blood Pressure Variability: The Spanish ABPM Registry. Hypertension (Dallas, Tex. : 1979), HYPERTENSIONAHA11914508. https://doi.org/10.1161/HYPERTENSIONAHA.119.14508
de la Sierra, Alejandro, et al. "Prognostic Relevance of Short-Term Blood Pressure Variability: The Spanish ABPM Registry." Hypertension (Dallas, Tex. : 1979) vol. (2020): HYPERTENSIONAHA11914508. doi: https://doi.org/10.1161/HYPERTENSIONAHA.119.14508
de la Sierra A, Banegas JR, Bursztyn M, Parati G, Stergiou G, Mateu A, Vinyoles E, Segura J, Gorostidi M, Ruilope LM. Prognostic Relevance of Short-Term Blood Pressure Variability: The Spanish ABPM Registry. Hypertension. 2020 Jan 27;HYPERTENSIONAHA11914508. doi: 10.1161/HYPERTENSIONAHA.119.14508. Epub 2020 Jan 27. PMID: 31983311.
Copy Download .nbib Format: NLM
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.

European heart journal

Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, Kolkhof P, Nowack C, Gebel M, Ruilope LM, Bakris GL.
PMID: 35023547
Eur Heart J. 2021 Nov 22; doi: 10.1093/eurheartj/ehab777. Epub 2021 Nov 22.

AIMS: The complementary studies FIDELIO-DKD and FIGARO-DKD in patients with type 2 diabetes and chronic kidney disease (CKD) examined cardiovascular and kidney outcomes in different, overlapping stages of CKD. The purpose of the FIDELITY analysis was to perform an...

Cite
Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2021;doi: 10.1093/eurheartj/ehab777.
Agarwal, R., Filippatos, G., Pitt, B., Anker, S. D., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Gebel, M., Ruilope, L. M., Bakris, G. L. (2021). Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. European heart journal, . https://doi.org/10.1093/eurheartj/ehab777
Agarwal, Rajiv, et al. "Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis." European heart journal vol. (2021). doi: https://doi.org/10.1093/eurheartj/ehab777
Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, Kolkhof P, Nowack C, Gebel M, Ruilope LM, Bakris GL. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2021 Nov 22; doi: 10.1093/eurheartj/ehab777. Epub 2021 Nov 22. PMID: 35023547.
Copy Download .nbib Format: NLM
Prediction of the early response to spironolactone in resistant hypertension by the combination of matrix metalloproteinase-9 activity and arterial stiffness parameters.

European heart journal. Cardiovascular pharmacotherapy

Rodríguez-Sánchez E, Navarro-García JA, Aceves-Ripoll J, González-Lafuente L, Baldan-Martin M, de la Cuesta F, Alvarez-Llamas G, Barderas MG, Segura J, Ruilope LM, Ruiz-Hurtado G.
PMID: 32663251
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 14; doi: 10.1093/ehjcvp/pvaa086. Epub 2020 Jul 14.

AIMS: The aim of present study was to determine whether arterial stiffness assessed with the biochemical parameter active matrix metalloproteinase (MMP)-9 and the clinical parameters pulse pressure (PP) and pulse wave velocity predicts the response to spironolactone in resistant...

Cite
Rodríguez-Sánchez E, Navarro-García JA, Aceves-Ripoll J, et al. Prediction of the early response to spironolactone in resistant hypertension by the combination of matrix metalloproteinase-9 activity and arterial stiffness parameters. Eur Heart J Cardiovasc Pharmacother. 2020;doi: 10.1093/ehjcvp/pvaa086.
Rodríguez-Sánchez, E., Navarro-García, J. A., Aceves-Ripoll, J., González-Lafuente, L., Baldan-Martin, M., de la Cuesta, F., Alvarez-Llamas, G., Barderas, M. G., Segura, J., Ruilope, L. M., & Ruiz-Hurtado, G. (2020). Prediction of the early response to spironolactone in resistant hypertension by the combination of matrix metalloproteinase-9 activity and arterial stiffness parameters. European heart journal. Cardiovascular pharmacotherapy, . https://doi.org/10.1093/ehjcvp/pvaa086
Rodríguez-Sánchez, Elena, et al. "Prediction of the early response to spironolactone in resistant hypertension by the combination of matrix metalloproteinase-9 activity and arterial stiffness parameters." European heart journal. Cardiovascular pharmacotherapy vol. (2020). doi: https://doi.org/10.1093/ehjcvp/pvaa086
Rodríguez-Sánchez E, Navarro-García JA, Aceves-Ripoll J, González-Lafuente L, Baldan-Martin M, de la Cuesta F, Alvarez-Llamas G, Barderas MG, Segura J, Ruilope LM, Ruiz-Hurtado G. Prediction of the early response to spironolactone in resistant hypertension by the combination of matrix metalloproteinase-9 activity and arterial stiffness parameters. Eur Heart J Cardiovasc Pharmacother. 2020 Jul 14; doi: 10.1093/ehjcvp/pvaa086. Epub 2020 Jul 14. PMID: 32663251.
Copy Download .nbib Format: NLM
Age and blood pressure goal in women with prior coronary events.

International Journal of Cardiology. Hypertension

Ruilope LM, Ruiz-Hurtado G.
PMID: 33447780
Int J Cardiol Hypertens. 2020 Oct 20;7:100059. doi: 10.1016/j.ijchy.2020.100059. eCollection 2020 Dec.

No abstract available.

Cite
Ruilope LM, Ruiz-Hurtado G. Age and blood pressure goal in women with prior coronary events. Int J Cardiol Hypertens. 2020;7:100059doi: 10.1016/j.ijchy.2020.100059.
Ruilope, L. M., & Ruiz-Hurtado, G. (2020). Age and blood pressure goal in women with prior coronary events. International Journal of Cardiology. Hypertension, 7100059. https://doi.org/10.1016/j.ijchy.2020.100059
Ruilope, Luis M, and Ruiz-Hurtado, Gema. "Age and blood pressure goal in women with prior coronary events." International Journal of Cardiology. Hypertension vol. 7 (2020): 100059. doi: https://doi.org/10.1016/j.ijchy.2020.100059
Ruilope LM, Ruiz-Hurtado G. Age and blood pressure goal in women with prior coronary events. Int J Cardiol Hypertens. 2020 Oct 20;7:100059. doi: 10.1016/j.ijchy.2020.100059. eCollection 2020 Dec. PMID: 33447780; PMCID: PMC7803045.
Copy Download .nbib Format: NLM
Cardiovascular Risk Stratification Based on Oxidative Stress for Early Detection of Pathology.

Antioxidants & redox signaling

Corbacho-Alonso N, Baldán-Martín M, López JA, Rodríguez-Sánchez E, Martínez PJ, Mourino-Alvarez L, Sastre-Oliva T, Cabrera M, Calvo E, Padial LR, Vázquez J, Vivanco F, Alvarez-Llamas G, Ruiz-Hurtado G, Ruilope LM, Barderas MG.
PMID: 34036803
Antioxid Redox Signal. 2021 Sep;35(8):602-617. doi: 10.1089/ars.2020.8254. Epub 2021 Jul 05.

No abstract available.

Cite
Corbacho-Alonso N, Baldán-Martín M, López JA, et al. Cardiovascular Risk Stratification Based on Oxidative Stress for Early Detection of Pathology. Antioxid Redox Signal. 2021;35(8):602-617doi: 10.1089/ars.2020.8254.
Corbacho-Alonso, N., Baldán-Martín, M., López, J. A., Rodríguez-Sánchez, E., Martínez, P. J., Mourino-Alvarez, L., Sastre-Oliva, T., Cabrera, M., Calvo, E., Padial, L. R., Vázquez, J., Vivanco, F., Alvarez-Llamas, G., Ruiz-Hurtado, G., Ruilope, L. M., & Barderas, M. G. (2021). Cardiovascular Risk Stratification Based on Oxidative Stress for Early Detection of Pathology. Antioxidants & redox signaling, 35(8), 602-617. https://doi.org/10.1089/ars.2020.8254
Corbacho-Alonso, Nerea, et al. "Cardiovascular Risk Stratification Based on Oxidative Stress for Early Detection of Pathology." Antioxidants & redox signaling vol. 35,8 (2021): 602-617. doi: https://doi.org/10.1089/ars.2020.8254
Corbacho-Alonso N, Baldán-Martín M, López JA, Rodríguez-Sánchez E, Martínez PJ, Mourino-Alvarez L, Sastre-Oliva T, Cabrera M, Calvo E, Padial LR, Vázquez J, Vivanco F, Alvarez-Llamas G, Ruiz-Hurtado G, Ruilope LM, Barderas MG. Cardiovascular Risk Stratification Based on Oxidative Stress for Early Detection of Pathology. Antioxid Redox Signal. 2021 Sep;35(8):602-617. doi: 10.1089/ars.2020.8254. Epub 2021 Jul 05. PMID: 34036803.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 85 entries